ライフサイエンスコーパス: v-Raf

1 ivated the MEK/ERK pathway as efficiently as v-Raf.

2 Ha-rasV12, which in turn was greater than by v-raf.

3 oblasts by v-crk, -src, and -ras, but not by v-raf.

4 block transformation mediated by v-H-Ras or v-Raf.

5 ed phosphorylation of protein kinase Balpha, v-raf-1 murine leukemia viral oncogene homolog 1 (i.e.,

6 V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1)

7 pathway, comprising the protein kinases RAF (v-raf-1 murine leukemia viral oncogene homolog 1), MEK1/

8 an cancers, due to mutations in RAS or BRAF (v-raf-1 murine leukemia viral oncogene homolog B1).

9 F1 (epithelial splicing regulatory protein-1-v-raf-1 murine leukemia viral oncogene homolog-1) gene f

10 f RhoA is required for efficient (V12)HaRas, V-Raf and (V600E)BRAF transformation and (V12)HaRas-medi

11 n, we treated rat 3Y1 fibroblasts expressing v-Raf and showed that the antibiotic blocked assembly of

12 by cotransfection with constitutively active v-raf and was blocked by the dominant-negative mutant, c

13 rea was increased by srcF527, Ha-rasV12, and v-raf, and although it altered myocyte morphology by cau

14 Various oncogenes such as c-Src, v-Raf, and Ras, and multiple environmental stimuli, incl

15 in REF-1 cells transformed by v-ras, v-src, v-raf, and v-fos.

16 nts to estradiol or stable expression of the v-raf construct yielded cells that extended processes at

17 but only in combination can they translocate v-Raf (delta gag) into the nucleolus.

18 is sufficient to translocate the cytoplasmic v-Raf (delta gag) into the nucleus, but only in combinat

19 authentic NoLS, BR2 was fused to cytoplasmic v-Raf (delta gag) kinase.

20 Several protein kinases (e.g. pp60(src), v-Raf) exist in heterocomplexes with hsp90 and a 50-kDa

21 ated kinase cascade (srcF527, Ha-rasV12, and v-raf) increased expression of "fetal" genes.

22 educed dramatically (6-8-fold) the number of v-raf-induced foci in transfected NIH3T3 cells.

23 oncogenic protein kinases, such as v-Src and v-Raf, into heterocomplexes that contain hsp90 and eithe

24 rising from the V600E mutation in the kinase v-RAF murine sarcoma viral oncogene homolog B (BRAF(V600

25 v-raf murine sarcoma viral oncogene homolog B (BRAF) and

26 e NPs efficiently silences the expression of V-Raf murine sarcoma viral oncogene homolog B (BRAF) in

27 hatase, receptor type, O cooperated with the v-raf murine sarcoma viral oncogene homolog B (BRAF) rec

28 Frequent somatic mutation of v-raf murine sarcoma viral oncogene homolog B (BRAF), a

29 ng rearranged during transfection (RET)/PTC, v-RAF murine sarcoma viral oncogene homolog B (BRAF), or

30 BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitor

31 Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) a

32 reviously identified activating mutations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (B

33 requently driven by mutational activation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) ac

34 Although melanomas with mutant v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) ca

35 at melanomas and to increase the duration of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) in

36 hibitor as single therapy or together with a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in

37 fenib and dabrafenib selectively inhibit the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) ki

38 We have shown previously that mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) me

39 henotype (CIMP), microsatellite instability, v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mu

40 issue of Blood, Xi and colleagues report on v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mu

41 discovery of cross-talk between the AMPK and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) si

42 ted protein kinase signaling pathway such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v

43 l transduction molecule has been identified: v-raf murine sarcoma viral oncogene homolog B1 (BRAF).

44 r (VEGF), rearranged during transfection and v-raf murine sarcoma viral oncogene homolog B1 pathways

45 5A3-BRAF (solute carrier family 45, member 3-v-raf murine sarcoma viral oncogene homolog B1) and ESRP

46 To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during m

47 and mutations sought in exon 15 of the BRAF (v-raf murine sarcoma viral oncogene homolog B1) gene usi

48 odine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutation

49 harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene

50 ptimization of a series of new inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF),

51 eceptor 2, anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma viral oncogene homologue B1, AKT, B

52 over, we show that, like Mos, both v-ras and v-raf oncogene products induce apoptosis in p53+/+ MEFs.

53 , nor could previous transformation with the v-raf oncogene.

54 resses the transforming activity of H-ras or v-raf oncogenes through ERK dephosphorylation and inacti

55 function of transformation by the Ha-ras and v-raf oncogenes, evaluations of the signaling and transc

56 ed morphological transformation by H-ras and v-raf oncogenes.

57 tion, we stably transfected H19-7 cells with v-raf or an oncogenic human Raf-1-estrogen receptor fusi

58 However, in contrast to v-Raf, RafS259 mutants failed to transform.

59 tially discovered in the viral Raf oncogene (v-Raf), results in a kinase domain with high basal activ

60 To obtain some insight as to how v-Raf selects predominantly hsp90.p50(cdc37) heterocompl

61 d the vimentin phosphopeptides isolated from v-raf-transfected cells labeled with orthophosphoric aci

62 emonstrate an association between Ha-ras and v-raf transformation of CREF cells with elevated PEA3 an

63 ic transforming genes, like v-abl, v-ras, or v-raf, which did not confer indefinite division potentia

64 o, we show that p50(cdc37) binds directly to v-Raf, with the catalytic domain of Raf being sufficient